In the last decades new pharmacodynamic properties of β-adrenoceptors have been
discovered that could greatly impact in the use of β-adrenergic agents in the clinical practice …

β-Adrenoceptor antagonists have revolutionized the management of heart failure in humans.
However, fundamental questions remain concerning their use. Currently, there is …

Asthma is one of the most common respiratory diseases, where inhalation and exhalation
are obstructed due to narrowing of the airways by broncho-constriction or by inflammation …

SUMMARY 1 In atrium and ventricle from failing and non‐failing human hearts, activation of
β1‐or β2‐adrenoceptors causes increases in contractile force, hastening of relaxation …

The human heart contains at least four distinct β-adrenoceptor subtypes, three of which have
been cloned. However, the binding properties of β-blockers to the different β-adrenoceptor …

The three β-adrenoceptor subtypes (β1, β2, β3) represent important therapeutic targets. The
use of β2-adrenoceptor agonists as bronchodilators and β1 or β1/β2 antagonists as …

The development of radioligand-binding studies has greatly advanced our knowledge of the
molecular pharmacology of [beta]-adrenoceptors. With this technique it is possible for the …

Abstract β-Adrenoceptors of the β 1 and β 2 subtypes classically mediate the effects of
catecholamines on the contractility of cardiac muscle and the relaxation of vascular smooth …

Publisher Summary β 2-adrenoceptor agonists are the most important bronchodilator
therapies available for the management of asthma and chronic obstructive pulmonary …

β-1 and β-2 adrenoceptors (AR) play a pivotal role in regulation of the activity of the
sympathetic nervous system and agonists and antagonists at both β AR subtypes are …